PTC Therapeutics Inc. (NASDAQ: PTCT) closed the day trading at $46.95 down -19.62% from the previous closing price of $58.41. In other words, the price has decreased by -$11.46 from its previous closing price. On the day, 5831438 shares were traded. PTCT stock price reached its highest trading level at $48.62 during the session, while it also had its lowest trading level at $42.23.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
For a better understanding of PTCT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.30 and its Current Ratio is at 1.40.
Upgrades & Downgrades
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 23 when Reeve Emma sold 2,652 shares for $59.53 per share. The transaction valued at 157,885 led to the insider holds 7,200 shares of the business.
Reeve Emma sold 7,116 shares of PTCT for $423,630 on May 22. The Director now owns 7,200 shares after completing the transaction at $59.53 per share. On May 22, another insider, Pauwels Eric, who serves as the CHIEF BUSINESS OFFICER of the company, sold 2,013 shares for $59.01 each. As a result, the insider received 118,791 and left with 47,553 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 4.08B and an Enterprise Value of 4.37B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.50. Its current Enterprise Value per Revenue stands at 5.68 whereas that against EBITDA is -12.13.
Stock Price History:
Over the past 52 weeks, PTCT has reached a high of $59.84, while it has fallen to a 52-week low of $25.01. The 50-Day Moving Average of the stock is 51.65, while the 200-Day Moving Average is calculated to be 46.93.
Over the past 3-months, PTCT traded about 774.04K shares per day on average, while over the past 10 days, PTCT traded about 1.26M shares per day. A total of 73.73M shares are outstanding, with a floating share count of 70.11M. Insiders hold about 0.10% of the company’s shares, while institutions hold 106.45% stake in the company. Shares short for PTCT as of Apr 27, 2023 were 5.22M with a Short Ratio of 5.22M, compared to 5.37M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 7.03% and a Short% of Float of 9.59%.
Current recommendations for the stock of the company come from 15 analysts. On average, analysts expect EPS of -$1.68 for the current quarter, with a high estimate of -$0.88 and a low estimate of -$3.04, while EPS last year was -$2.13. The consensus estimate for the next quarter is -$1.29, with high estimates of -$0.51 and low estimates of -$1.86.
Analysts are recommending an EPS of between -$3.6 and -$5.97 for the fiscal current year, implying an average EPS of -$4.88. EPS for the following year is -$3.68, with 16 analysts recommending between -$1.27 and -$7.5.
13 analysts predict $204.46M in revenue for the current quarter. It ranges from a high estimate of $238.1M to a low estimate of $182.89M. As of the current estimate, PTC Therapeutics Inc.’s year-ago sales were $165.53M, an estimated increase of 23.50% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $221.57M, an increase of 18.60% less than the figure of $23.50% in the same quarter last year. There is a high estimate of $267.11M for the next quarter, whereas the lowest estimate is $200.21M.
A total of 16 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $1.01B, while the lowest revenue estimate was $912.68M, resulting in an average revenue estimate of $961.69M. In the same quarter a year ago, actual revenue was $698.8M, up 37.60% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $962.87M in the next fiscal year. The high estimate is $1.15B and the low estimate is $821.89M. The average revenue growth estimate for next year is up 0.10% from the average revenue estimate for this year.